CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma
Authors
Keywords
-
Journal
Cancer Medicine
Volume 5, Issue 3, Pages 398-406
Publisher
Wiley
Online
2016-01-14
DOI
10.1002/cam4.585
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group
- (2014) D. A. Eichenauer et al. BLOOD
- Current status of prognostication in classical Hodgkin lymphoma
- (2014) Girish Venkataraman et al. BRITISH JOURNAL OF HAEMATOLOGY
- The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale
- (2014) A. Gallamini et al. HAEMATOLOGICA
- Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
- (2014) Sally F. Barrington et al. JOURNAL OF CLINICAL ONCOLOGY
- Interim 18F-FDG PET SUVmax Reduction Is Superior to Visual Analysis in Predicting Outcome Early in Hodgkin Lymphoma Patients
- (2014) C. Rossi et al. JOURNAL OF NUCLEAR MEDICINE
- CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment
- (2014) Mohamed Touati et al. LEUKEMIA & LYMPHOMA
- CD68 staining correlates with the size of residual mass but not with survival in classical Hodgkin lymphoma
- (2014) Ariel Agur et al. LEUKEMIA & LYMPHOMA
- PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA
- (2014) Annarosa Cuccaro et al. Mediterranean Journal of Hematology and Infectious Diseases
- Treatment-Related Mortality in Patients With Advanced-Stage Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group
- (2013) Diana Wongso et al. JOURNAL OF CLINICAL ONCOLOGY
- Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma
- (2012) Maike Sauer et al. AMERICAN JOURNAL OF HEMATOLOGY
- Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial
- (2012) K. L. Tan et al. BLOOD
- Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma
- (2012) K. Jones et al. CLINICAL CANCER RESEARCH
- Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma
- (2012) B. Sanchez-Espiridion et al. HAEMATOLOGICA
- Gene Expression–Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma
- (2012) David W. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of FOXP3, CD68, and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma Is Predictive of Outcome
- (2012) Paul Greaves et al. JOURNAL OF CLINICAL ONCOLOGY
- Gonadal Function and Fertility in Survivors After Hodgkin Lymphoma Treatment Within the German Hodgkin Study Group HD13 to HD15 Trials
- (2012) Karolin Behringer et al. JOURNAL OF CLINICAL ONCOLOGY
- Hodgkin's lymphoma in adults
- (2012) William Townsend et al. LANCET
- A 10-year experience with treatment of high and standard risk Hodgkin disease: Six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved
- (2011) Eldad J. Dann et al. AMERICAN JOURNAL OF HEMATOLOGY
- Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma
- (2011) D. Azambuja et al. ANNALS OF ONCOLOGY
- Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
- (2011) C. H. Moskowitz et al. BLOOD
- The Viral Load of Epstein-Barr Virus (EBV) DNA in Peripheral Blood Predicts for Biological and Clinical Characteristics in Hodgkin Lymphoma
- (2011) S. Hohaus et al. CLINICAL CANCER RESEARCH
- Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma
- (2011) W. J. Plattel et al. HAEMATOLOGICA
- Optimal Therapy of Advanced Hodgkin Lymphoma
- (2011) R. Advani Hematology-American Society of Hematology Education Program
- Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses
- (2010) Andrea Gallamini et al. BRITISH JOURNAL OF HAEMATOLOGY
- Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma
- (2010) P. Kamper et al. HAEMATOLOGICA
- Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
- (2010) Christian Steidl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma
- (2009) A. Avigdor et al. ANNALS OF ONCOLOGY
- Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study
- (2009) Andreas Engert et al. JOURNAL OF CLINICAL ONCOLOGY
- Report on the First International Workshop on interim-PET scan in lymphoma
- (2009) Michel Meignan et al. LEUKEMIA & LYMPHOMA
- Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22
- (2008) Marijke Niens et al. BRITISH JOURNAL OF HAEMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More